Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

319.52
-10.8200-3.28%
Post-market: 319.520.00000.00%19:58 EDT
Volume:1.31M
Turnover:414.93M
Market Cap:42.21B
PE:137.13
High:322.35
Open:319.48
Low:313.54
Close:330.34
52wk High:495.55
52wk Low:205.87
Shares:132.11M
Float Shares:126.15M
Volume Ratio:1.21
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.33
EPS(LYR):2.33
ROE:73.28%
ROA:6.81%
PB:53.49
PE(LYR):137.13

Loading ...

Alnylam Pharmaceuticals to Unveil Five-Year Strategy at J.P. Morgan Healthcare Conference

Reuters
·
Jan 05

It’s Earnings Warning Season. How to Profit From Others’ Misery

Dow Jones
·
Jan 01

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-12-31

Reuters
·
Jan 01

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2025-12-23

Reuters
·
Dec 24, 2025

Peptidream And Alnylam Announce Achievement Of Key Milestone In Sirna Conjugate Discovery Collaboration

Reuters
·
Dec 18, 2025

PeptiDream Achieves Preclinical Milestone in siRNA Delivery Collaboration with Alnylam

Reuters
·
Dec 18, 2025

From on-device AI to the 'girlfriend index,' trading ideas from the research firm that nailed 2025's investment themes

Dow Jones
·
Dec 18, 2025

BRIEF-Alnylam To Invest $250 Million To Add Enzymatic Ligation Platform

Reuters
·
Dec 17, 2025

Alnylam Invests $250 Million to Expand RNAi Drug Manufacturing in Massachusetts

Reuters
·
Dec 17, 2025

Alnylam Pharmaceuticals Inc - New Capabilities Operational by Late 2027

THOMSON REUTERS
·
Dec 17, 2025

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for Rnai Therapeutics

THOMSON REUTERS
·
Dec 17, 2025

BRIEF-Alnylam Announces Health Canada Approval Of Amvuttra®

Reuters
·
Dec 16, 2025

Alnylam Announces Health Canada Approval of Amvuttra® (Vutrisiran), the First and Only Rnai Therapeutic for the Treatment of Cardiomyopathy in Adult Patients With Attr Amyloidosis

THOMSON REUTERS
·
Dec 16, 2025

Is Alnylam (ALNY) Using Nasdaq 100 Inclusion To Quietly Redefine Its Capital Allocation Playbook?

Simply Wall St.
·
Dec 16, 2025

Alnylam Pharmaceuticals Is Maintained at Market Perform by Leerink Partners

Dow Jones
·
Dec 16, 2025

Alnylam Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $351 From $370

THOMSON REUTERS
·
Dec 15, 2025

Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut

Dow Jones
·
Dec 14, 2025

Nasdaq Says Biogen, CDW Corporation, Globalfoundries, Lululemon Athletica, On Semiconductor, Trade Desk Will Be Removed From Nasdaq 100 Index

Reuters
·
Dec 13, 2025

Seagate, Western Digital And Other Four Companies Will Be Added To Nasdaq 100 Index, While Lululemon, ON Semi, Trade Desk And Other Three Companies Will Be Removed

THOMSON REUTERS
·
Dec 13, 2025

Nasdaq Inc: Alnylam Pharmaceuticals, Ferrovial, Insmed, Monolithic Power Systems, Seagate Technology, Western Digital Will Be Added to Nasdaq 100 Index

THOMSON REUTERS
·
Dec 13, 2025